Indeed, SGLT2 inhibitors have shown to reduce the risk of cardiovascular outcomes and mortality, and real-life data support contemporary society recommendations to prioritize their use in patients with diabetes mellitus and at high risk for cardiovascular complications (33). This evidence concerns the gene SLC5A2 and diabetes mellitus.